Zobrazeno 1 - 10
of 14
pro vyhledávání: '"Jane Meisel"'
Publikováno v:
Therapeutic Advances in Medical Oncology, Vol 14 (2022)
The treatment of hormone receptor-positive, HER2-negative breast cancer has become increasingly individualized, thanks to the development of genomic testing. Gene expression assays provide clinicians and patients with both prognostic and predictive i
Externí odkaz:
https://doaj.org/article/7dfd3e4b2f7946dc9d2fbf293bdd97a2
Publikováno v:
Gynecologic Oncology Reports, Vol 19, Iss C, Pp 18-21 (2017)
Extrarenal Wilms' tumor of the ovary is a very rare tumor likely derived from embryonic mesonephros. We present the first reported case of a teratoid extrarenal Wilms' tumor of the ovary with a short review of the existing literature. In the case, a
Externí odkaz:
https://doaj.org/article/8ddfd5535a314da0aec3d41a20188489
Autor:
Rani Bansal, Julie McGrath, Phil Walker, Matias A. Bustos, Estelamari Rodriguez, Sarah L. Sammons, Melissa K. Accordino, Jane Meisel, Margaret Gatti-Mays, Emily Hsu, Kate I. Lathrop, Virginia Kaklamani, Matthew Oberley, W. Michael Korn, Stephanie L. Graff
Publikováno v:
Cancer Research. 83:HER2-12
Introduction: Breast cancer has pioneered precision medicine with prognostic and predictive subtypes, defined by immunohistochemistry (IHC). Novel therapeutic strategies have led to the emergence of HER2-Low (H2L) as a new entity, defined as tumors w
Autor:
Jane Meisel, Sarah L. Sammons, Kelly Shanahan, Timothy Pluard, Monica Kozlowski, Dominic Carroll, Elizabeth Attias
Publikováno v:
Cancer Research. 83:P6-09
Introduction: In patients (pts) with ER+/HER2- mBC, acquired ESR1 mutations after endocrine therapy can lead to treatment resistance, metastasis, and poor prognosis. The objective of this survey was to understand the knowledge of NGS in pts with mBC.
Autor:
Erica L. Mayer, Yue Ren, Nikhil Wagle, Reshma Mahtani, Cynthia Ma, Angela DeMichele, Massimo Cristofanilli, Jane Meisel, Kathy D. Miller, Trevor Jolly, Elizabeth Riley, Rubina Qamar, Priyanka Sharma, Sonya Reid, Natalie Sinclair, Meredith Faggen, Caroline Block, Naomi Ko, Ann Partridge, Wendy Y. Chen, Michelle K. DeMeo, Victoria Attaya, Amanda Okpoebo, Yuan Liu, Eric Gauthier, Harold Burstein, Meredith Regan, Sara Tolaney
Publikováno v:
Cancer Research. 83:GS3-06
Background CDK4/6 inhibitors (CDK4/6i) in combination with endocrine therapy (ET) have a well-established role in the management of hormone receptor-positive (HR+)/HER2- metastatic breast cancer (MBC). The benefit of continuing CDK4/6i beyond progres
Autor:
Sarah L. Sammons, Jane Meisel, Kelly Shanahan, Timothy Pluard, Monica Kozlowski, Dominic Carroll, Elizabeth Attias
Publikováno v:
Cancer Research. 83:P6-09
Introduction: In patients (pts) with ER+/HER2- mBC, insights into the foremost concerns regarding their mBC treatment goals and QOL are often assumed by providers but are vastly understudied. The objectives of this survey were to better comprehend tr
Autor:
Patrick Dillon, Reva Basho, Hyo S. Han, Hans-Christian Kolberg, Katherine Tkaczuk, George Zahrah, Maria Gion, Herman Voss, Jane Meisel, Timothy Pluard, Jenny Fox, Mafalda Oliveira, Ursa Brown-Glaberman, Erica Stringer-Reasor, Luis Manso, Sherko Küemmel, Lin Chi Chen, Sheng Wu, Brandon Croft, Valentina Boni
Publikováno v:
Cancer Research. 83:OT1-03
Background Patients with metastatic triple-negative breast cancer (mTNBC) have a poor prognosis. Treatment combinations of anti-programmed death protein 1 (anti–PD-1) agents with chemotherapy have shown promise in mTNBC. Ladiratuzumab vedotin (LV)
Autor:
Caitlin Taylor, Jane Meisel, Aimee J. Foreman, Christy Russell, Dipankar Bandyopadhyay, Xiaoyan Deng, Lisa Floyd, Amelia Zelnak, Harry Bear, Ruth O’Regan
Purpose The role of neoadjuvant endocrine therapy in the treatment of patients with early-stage, hormone receptor-positive (HR +) breast cancer is not well defined. Tools to better determine which patients may benefit from neoadjuvant endocrine thera
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::83b8a1128726571c675738adb05ddd35
https://doi.org/10.21203/rs.3.rs-2228265/v1
https://doi.org/10.21203/rs.3.rs-2228265/v1
Autor:
Jennifer Yen, Leylah Drusbosky, Caroline Weipert, Nicole Zhang, David Hanna, Catalin Barbacioru, Hao Wang, Alex Artyomenko, Arielle Yablonovitch, Yu Fu, Aaron Hardin, Nagesh Alla, Robert Foley, Max Maligska, Bhargavi Panchangam, Phil Yen, Jane Meisel, Neelima Vidula, Massimo Cristofanilli, Jeremy Force, Michael Dorschner, Martina Lefterova, Elena Helman, Becky Nagy, Darya Chudova, AmirAli Talasaz
Publikováno v:
Cancer Research. 82:P5-13
Background: Inactivating HRR gene mutations can lead to HRR deficiency (HRD) and predict response to PARPi therapy in patients with breast cancer. Copy number loss and large genomic rearrangements (LGR) can result in HRD but are challenging to detect
Autor:
Esther Rose, Melanie Walker Hardy, Rachael Gates, Christine Stanislaw, Jane Meisel, Karen Arnovitz Grinzaid
Publikováno v:
Public Health Genomics. 25:141-154
Introduction: Ashkenazi Jewish (AJ) individuals face a 1 in 40 (2.5%) risk of having a BRCA mutation, which is 10 times the general population risk. JScreen launched the PEACH BRCA Study, a telehealth-based platform for BRCA education and testing, wi